Kenneth

🇩🇰

[Ida Bogac @albtur_mnymkrs]

Today, cancer vaccine recipients walked the halls of Congress and stood before lawmakers not as statistics, but as people who are alive today because science refused to give up.

The future of cancer treatment was standing at the podium. $nwbo #dcvax

[Hoffmann @hoffmann6383]

➡️NWBO Spoofing Lawsuit - May 29th Status Update

The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)

The Docket: https://t.co/FhgxuPIxim

On May 29, 2026 the parties in the above case jointly filed a discovery status update with the Court. We have the usual back-and-forth finger pointing. Instead of wasting time analyzing the finger pointing I'll address some of the more interesting tidbits found in this letter.

✅ $NWBO is going after Defendant Market Makers' Algorithms

"For example, Defendants have yet to produce algorithms underlying the relevant trading. No party has produced these algorithms despite the Court’s prior acknowledgment that they are discoverable,6 with Citadel asserting it did not use trading algorithms at all.7"

✅ Document Production

NWBO: 4,508
Citadel: 257
G1X: 156
GTS: 229
Instinet: 69
Lime: 20
Virtu: 92

See Image 1.

✅ $NWBO is going for information related to short selling

“Defendants suggest that by searching for terms related to shorting, NWBO is fishing. Not so. While the Court stated that short selling was not required among the mechanisms of the spoofing scheme, short selling is directly tied to profit motive incentives underlying the alleged activity.”

✅ $NWBO is seeking all trading data

This includes ALL trading done from every Defendant from December '17 to the present.

"Without access to Defendants’ complete trading data, Plaintiff is unduly restricted in evaluating Defendants’ bona fide market-making trading patterns versus their manipulative spoofing tactics and unduly limited in proving scienter or furthering its claim for injunctive relief for alleged, ongoing harm."

We should expect to see a motion to compel filed by $NWBO if this matter is not resolved:

"Discovery in connection with that claim should necessarily extend from December 5, 2017 to the present day. Defendants’ attempt to limit their searches is unsupported and contrary to their prior representations. As the parties are at an impasse, NWBO anticipates it will need to bring a motion to compel in the coming weeks."

✅ $NWBO seeks materials related to Defendants' regulatory investigations

"NWBO has also raised the absence of materials regarding regulatory and internal investigations, including SEC investigations, into potential related misconduct, as well as data regarding short sales."

[Hoffmann @hoffmann6383]

➡️Is Citadel attempting to use discovery in NWBO’s spoofing case to get a sneak peak at other market manipulation investigations into Citadel?

The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)

The Docket: https://t.co/FhgxuPIxim

$NWBO has sued seven of the largest market makers in the world alleging that they have illegally manipulated $NWBO’s share price via spoofing. One of the seven defendants (Canaccord) has entered a confidential settlement agreement. The other six market makers are going through discovery. As part of their discovery, Citadel sent a subpoena to Joshua Mitts, $NWBO’s non-testifying expert and attorney. The Court entered a Protective Order limiting the documents Citadel and the other Defendants are able to obtain from Mr. Mitts via subpoena. In a letter dated June 2nd, 2026, Mr. Mitts’ attorney is asking the Court to further limit the subpoena to documents in his possession that are related to the $NWBO lawsuit instead of all documents in his possession.

Why are the attorneys of Mr. Mitts asking the Court to further narrow the scope of Mr. Mitts' subpoena?

In short, because Mr. Mitts is in possession of other documents concerning market manipulation by Citadel in unrelated matters.

Recall, Mr. Mitts’ CV states that he “has extensive experience supporting the U.S. Department of Justice.” [1]

The June 2nd letter from Mr. Mitts' attorneys to the Court states, in relevant part:

“…Mr. Mitts possesses documents which concern market manipulation or spoofing activity by Citadel in a number of unrelated matters. While those documents are technically responsive to Request No. 4, which seeks all such documents related to Citadel, such documents are irrelevant and confidential, and many are subject to privileges owned by third parties and/or require Mr. Mitts to notify third parties prior to any disclosure regarding them. In some cases, the matters in which Mr. Mitts has been involved are sufficiently sensitive that even the limited information a categorical log would require could not be disclosed to Citadel without violating privilege or confidentiality obligations.” (emphasis added)

Could Citadel be fishing for information on possible U.S. Department of Justice Investigations into themselves?

It's certainly possible, but this this letter doesn't provide any definitive answers.

[1]https://t.co/fn7IdPqRna

[Kenneth @Kenneth83risom]

@jaygreco194737 Don't wanna jinx it but starting to hope it just will happen this year

[G @Hamnakedshorts]

Hey FBI here is proof of how Left works. The pick tgt and then NAKED SHORT before report as you can see The FTD’s of 7.2MILLION shares. Then they attack
looks to ,me like they made $10 X7= $70M on this crime
add in real shorts $100-150M stolen

[kristen shaughnessy @kshaughnessy2]

People used to believe that, but they’ve woken up.

Apparently you haven’t seen the hundreds of real time examples we’ve provided

Who is protecting small public companies?
Why did Northwest Biotherapeutics have to take its promising and effective brain cancer treatment overseas to get away from market manipulation that has threatened to destroy the company? $NWBO

Why do so many small public companies have to sue to get trading data and why do market makers and regulators fight so hard against it?

And this 👇👇👇 (see post below) would never happen if trade settlement was enforced.

That is one of hundreds of examples we’ve posted and provided in reports to politicians on both sides of the aisle.
Big political donors don’t want you looking into any of this.

[SemperFITrader @SouthernDrive21]

$NWBO New Dockets on Mr Mitts. Docket 287 is essentially Mitts telling Judge Stein:
"I will log NWBO-related materials as ordered, but I should not have to identify or disclose privileged documents from completely unrelated cases involving Citadel."
Mitts explicitly tells the Court:
He did not use, adapt, compare, or rely upon analyses from other matters when performing work related to NWBO.

[Kenneth @Kenneth83risom]

Well this is not a fun day

$nwbo going below 0.2

[Lou Smith 🍀 @smith348572]

$NWBO

@zubirahmed
@Siobhain_Mc
@Keir_Starmer
@wesstreeting
@METhompson72
@biggercapital

After more than 2.5 years in the MHRA process, the question is no longer whether a decision should be made on DCVax-L — the question is why a decision still has not been made.

At this point, I cannot help but wonder whether powerful interests are benefiting from continued delay. Every month that passes forces Northwest Biotherapeutics to raise additional capital, diluting shareholders and weakening the company financially. Whether intentional or not, the effect is the same.

It is also impossible to ignore the broader context. Northwest Biotherapeutics is currently pursuing litigation in the United States against several major market makers, alleging manipulative trading practices, including spoofing. These are some of the most powerful participants in the global financial system.

While I have no evidence that any regulatory body has been improperly influenced, it is fair to ask difficult questions when a company involved in such litigation experiences extraordinary delays. Large financial institutions often possess extensive networks of influence throughout the financial ecosystem. It is therefore reasonable for investors to question whether forces that benefit from delay may also be working, directly or indirectly, to prolong uncertainty surrounding this application.

The UK has repeatedly stated its ambition to become a global leader in cell and gene therapies. If that is truly the goal, this case sends exactly the wrong message to investors around the world.

Capital is the lifeblood of medical innovation. Investors fund the research, the clinical trials, the manufacturing infrastructure, and ultimately the therapies that patients desperately need. When a promising therapy remains in regulatory limbo for years, confidence in the system is damaged.

DCVax-L has demonstrated long-term survival benefits in glioblastoma, one of the deadliest forms of cancer. Approximately 13.5% of patients were alive at five years versus roughly 5% under standard care, with a long-tail survival benefit and minimal toxicity.

Meanwhile, patients continue to wait.
Investors continue to wait.
Doctors continue to wait.
The scientific community continues to wait.

Regardless of the final outcome, the MHRA owes patients, physicians, researchers, investors, and the public a clear and timely decision.

If the UK wishes to remain a destination for biotechnology investment and a leader in advanced therapies, transparency, predictability, and timely regulatory action are essential.

Two and a half years is enough.

https://t.co/Tg3T4Mvkuf

[JoeRetired @joeretired41]

$NWBO

OTCMarkets level 2 data ASK looks interesting several MMs not showing and multiple OTCN Ask up to $2.99. Also, interesting all non MM Ask arein amounts that are not 2500 shares.

[SemperFITrader @SouthernDrive21]

$NWBO CTBVEAG and CHM Minutes Discussion

So my take is these do relate very closely and matches up, CHM took place 3/4 days after CTBVEAG.

"First take out the CLINICAL TRIAL APPLICATION related paragraph, has nothing to do with DCVAX IMO, this most likely was related to a newer experimental glioblastoma trial for TGX-007/Trogenix, It was being prepared for a UK trial opening in early 2026."

IMO these statements below relate to DCVAX from both initial CTBVEAG and CHM since I too can find no other application in late stages for brain cancer. Question is what were the points raised and have they now been addressed since we are 6 months post CTBVEAG comments. That is a positive as application is still active and final decision pending. It's very well possible any pending items were resolved.

CTBVEAG https://t.co/4YxlIUUCk2

LICENSING

NEW PRODUCTS (not previously licensed in the United Kingdom)The Expert Advisory Group considered the MHRA’s evaluation of a medicine indicated to treat adults with brain cancer. The Group discussed the grounds for non-acceptance and agreed with the points raised.

CHM Minutes https://t.co/inHyui8FSn

LICENSING

NEW DRUGS (not previously licensed in the United Kingdom) The Commission considered and advised on an application for a marketing authorisation fora medicinal product used to treat glioblastoma (a cancer of the brain).

Noted members who attended CTBVEAG meeting,two others were absent

Professor Farzin Farzaneh DPhil FRCPath FRSB Professor of Molecular Medicine, King’s College LondonHonorary Consultant in Specialist Medicine, King’s College Hospital NHS TrustProfessor

Chris Goldring BSc PhD PGCert FBPhSProfessor of Pharmacology, Department of Pharmacology and Therapeutics, The University ofLiverpool.

Dr Robin Thorpe PhD FRCPathRetired, Head, Division of Biotherapeutics, National Institute for Biological Standards andControl (NIBSC)

Professor Merryn Voysey DPhilProfessor of Statistics in Vaccinology, Oxford Vaccine Group, Department of Paediatrics,University of Oxford.

[AngstromUnit @AngstromU]

$nwbo

[Tommy Bax 🇬🇧 🇹🇼 🇪🇺 @TomBaxers]

My thoughts on the recently published CTBVEAG meeting minutes and why I do NOT believe this is a major roadblock to the approval of DCVax-L:

https://t.co/rkNL0caDKY

$NWBO

[SemperFITrader @SouthernDrive21]

$NWBO Latest Docket & Exibits Analysis from May 29th

[Stephanie 🇬🇧🇺🇸🦍 @stephmase22]

📣📣NWBO THREATENS MOTION TO COMPEL 🤔🤔

It is clear that Citadel Securities and Brokers are terrified of discovery.

In legal battles they will do what ever it takes to minimize the claims so they can get the case dismissed and avoid discovery.

As they were not successful in getting the case dismissed they are basically ignoring the discovery request with excuses. Such as overboard, burdensome and fishing.

A motion to compel is used in such cases when defendants are not complying with discovery request.

DISCOVERY IS THEIR WORST NIGHTMARE‼️

[JoeRetired @joeretired41]

@JackNdreu NWBO -url:discord -"https://t.co/Iy4XSeqECf" -url:linktr -url:xtrades - telegram - crypto

[Kenneth @Kenneth83risom]

@joeretired41 @JackNdreu That helped a lot thank you 🫡

[Kenneth @Kenneth83risom]

@JackNdreu Yeah it's getting crazy with this intense spam

[SemperFITrader @SouthernDrive21]

$NWBO New Dockets.. There is 63 pages mostly Exhibits but here is first 8 main pages which has Defendents and NWBO's position on the discovery documents.

MM's are stonewalling, out of 6 mm's they only produced 823 documents! and NWBO has produced 4508 documents, read the our response to Judge, they do not want to give us anything in discovery to uncover all the corruption and harm they caused to our stock.

[NWBOstacks @EatYerShorts]

$NWBO Joint Discovery Letter just dropped (63 pages)

Light on agreements. Heavy on arguments.

Here's both sides' stances straight from the docs:

NWBO's position:

• Produced 61k+ docs total (just added 1k+ on May 29), fixed most search terms, and keep compromising.

• Brokers produced pathetic 823 total: Citadel 257, others scraping scraps. Zero comms, barely any non-public docs, no algos.

• Demanding full productions + complete privilege logs by June 26, real trading data, spoof analyses, proper custodians, and broader relevant periods.

• MM's searches are weak, unilateral, and laughably narrow.

MM's position:

• NWBO's demands are overbroad, late, burdensome, and fishing. We've given enough on spoof episodes and trading data.

• NWBO's dragging with delays, zero analyses produced, and unrealistic asks.

• Our productions are complete and tailored per court rulings. No need for more.
----

This beef is nuclear on hit counts, time windows, RFPs, and stonewalling.

NWBO threatens Motion to Compel.

Magistrate Stein's about to drop the gavel.